On Tuesday, Cytek BioSciences Inc (NASDAQ: CTKB) opened higher 3.13% from the last session ,before settling in for the closing price of $6.70. Price fluctuations for CTKB have ranged from $3.80 to $12.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 36.02% over the past five years. Company’s average yearly earnings per share was noted -77.78% at the time writing. With a float of $119.19 million, this company’s outstanding shares have now reached $130.71 million.
Let’s look at the performance matrix of the company that is accounted for 676 employees.
Cytek BioSciences Inc (CTKB) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Cytek BioSciences Inc is 8.90%, while institutional ownership is 60.16%. The most recent insider transaction that took place on Mar 19 ’24, was worth 134,200. In this transaction CHIEF TECHNOLOGY OFFICER of this company sold 20,000 shares at a rate of $6.71, taking the stock ownership to the 6,010,402 shares. Before that another transaction happened on Mar 18 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 20,000 for $6.77, making the entire transaction worth $135,400. This insider now owns 6,030,402 shares in total.
Cytek BioSciences Inc (CTKB) Latest Financial update
If we go through the results of last quarter, which was made public on 12/30/2023, the company posted $0.04 earnings per share (EPS) for the quarter, besting the agreed prediction (set at $0) by $0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -77.78% per share during the next fiscal year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
Check out the current performance indicators for Cytek BioSciences Inc (CTKB). In the past quarter, the stock posted a quick ratio of 5.89. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.68. Likewise, its price to free cash flow for the trailing twelve months is 1434.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.09, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach 0.16 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
Cytek BioSciences Inc (NASDAQ: CTKB) saw its 5-day average volume 0.66 million, a negative change from its year-to-date volume of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 67.03%. Additionally, its Average True Range was 0.39.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 40.14%, which indicates a significant decrease from 87.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 33.87% in the past 14 days, which was lower than the 69.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.56, while its 200-day Moving Average is $7.40. Nevertheless, the first resistance level for the watch stands at $7.07 in the near term. At $7.22, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.43. If the price goes on to break the first support level at $6.71, it is likely to go to the next support level at $6.50. The third support level lies at $6.35 if the price breaches the second support level.
Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats
There are currently 130,824K shares outstanding in the company with a market cap of 903.97 million. Presently, the company’s annual sales total 193,020 K according to its annual income of -12,150 K. Last quarter, the company’s sales amounted to 58,230 K and its income totaled 5,500 K.
